Bernatowska E, Weremowicz R, Janowicz W, Madaliński K
Arch Immunol Ther Exp (Warsz). 1986;34(4):377-84.
Eight children aged 2 to 16 years who were diagnosed as having primary humoral immunodeficiency were treated with fresh plasma substitution, during the first 2 years. Subsequently these children and 5 other children with primary humoral immunodeficiency (ID) were treated during the next 10 months with intravenous preparation of IgG. Eight children received doses of 500 mg/kg body weight (group A), while five children received doses of 150 mg/kg (group B) at monthly intervals. After five months of this therapy the average increase of IgG concentration was in group A--395 mg/dl, while in group B--100 mg/dl, the difference being statistically significant. Substitution therapy with intravenous IgG was more effective than therapy with fresh plasma and caused appreciable clinical improvement. Only in one out of 130 cases of intravenous injections mild post-transfusion reaction was observed.
8名年龄在2至16岁之间被诊断为原发性体液免疫缺陷的儿童在最初2年接受了新鲜血浆置换治疗。随后，这些儿童以及另外5名原发性体液免疫缺陷（ID）儿童在接下来的10个月里接受了静脉注射免疫球蛋白治疗。8名儿童接受了500毫克/千克体重的剂量（A组），而5名儿童每月接受150毫克/千克的剂量（B组）。经过5个月的这种治疗，A组免疫球蛋白浓度的平均增加量为395毫克/分升，而B组为100毫克/分升，差异具有统计学意义。静脉注射免疫球蛋白替代疗法比新鲜血浆疗法更有效，并带来了明显的临床改善。在130例静脉注射病例中，仅观察到1例轻微的输血后反应。
